Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gritstone bio
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
September 30, 2024
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 09, 2024
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite
April 01, 2024
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
March 05, 2024
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
October 11, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
September 27, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 09, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 11, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 09, 2023
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Gritstone bio
Via
GlobeNewswire
Tickers
GRTS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.